Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

This study is testing whether adding everolimus (a targeted drug that blocks cancer cell growth) to standard chemotherapy improves outcomes for patients with advanced gallbladder cancer that cannot be surgically removed. Gallbladder cancer is rare and often diagnosed at a late stage, so researchers are looking for more effective treatments. **You may be eligible if...** - You have been diagnosed with advanced (stage III or IV) gallbladder cancer that cannot be removed surgically - You have not yet received chemotherapy for advanced disease (or received it more than 6 months ago as a preventive measure after surgery) - Your blood counts, liver, and kidney function meet required levels - Your blood sugar is not severely elevated - Your general health allows participation (ECOG score 0–2) **You may NOT be eligible if...** - You have uncontrolled infections, heart failure, or unstable angina - You had a heart attack within the last 6 months - You are pregnant - You are using medications that cannot be safely combined with the study drugs Talk to your doctor to see if this trial is right for you.